Losmapimod

Losmapimod (GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pKis of 8.1 and 7.6 for p38α and p38β, respectively[1].

Product Specifications

CAS Number

[585543-15-3]

Product Name Alternative

GSK-AHAB; GW856553X; SB856553

UNSPSC

12352005

Hazard Statement

H361

Target

Autophagy; p38 MAPK

Type

Reference compound

Related Pathways

Autophagy; MAPK/ERK Pathway

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/Losmapimod.html

Concentration

10mM

Purity

99.94

Solubility

DMSO : 27.5 mg/mL (ultrasonic) |Ethanol : 33.33 mg/mL (ultrasonic)

Smiles

CC1=C(C2=NC=C(C(NCC(C)(C)C)=O)C=C2)C=C(C(NC3CC3)=O)C=C1F

Molecular Formula

C22H26FN3O2

Molecular Weight

383.46

Precautions

H361

References & Citations

[1]Willette RN, et al. Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. J Pharmacol Exp Ther. 2009 Sep;330 (3) :964-70.|[2]Zhang XM, et al. Suppression of mitochondrial fission in experimental cerebral ischemia: The potential neuroprotective target of p38 MAPK inhibition. Neurochem Int. 2015 Nov;90:1-8.